For Libraries For Publication Open Access Downloads About Us Contact Us
Paper Titles
Active Rehabilitation Gloves Based on Brain-Computer Interfaces and Deep Learning
p.49
Multiple Channels Model Based on Mel Spectrogram for Classifying Abnormalities in Lung Sound
p.63
Electrosprayed Chitosan Nanoparticles for Drug Carriers in Cancer Treatment - A Mini Review
p.73
The Effect of Curcumin on Blood Glucose Patients with Type 2 Diabetes Mellitus: A Systematic Review
p.91
Public Perception of the Chemical Composition of Covid-19 Vaccine that Hinders the Implementations of COVID-19 Vaccination in Indonesia
p.101
Alcohol-Based Hand Sanitizer Combination of Eucalyptus Oil Extract against Aspergillus Niger Fungus
p.111
Synthesis of Colloidal Silver Nanoparticles Using Alginate as Reducing and Stabilizing Agents and its Application as Antibacterial Material
p.119
Kinetics of Essential Oil Extraction of Kaffir Lime Peel Using Microwave Assisted Hydrodistillation
p.129
The Fragility of Glassy Corn Starches
p.141

Public Perception of the Chemical Composition of Covid-19 Vaccine that Hinders the Implementations of COVID-19 Vaccination in Indonesia

Article Preview

Abstract:

Indonesia has been facing COVID-19 since March 2020, causing significant problems for public health. Indonesia is trying to solve this problem, and the vaccination program began in January 2021. Several obstacles include public acceptance of the composition of the COVID-19 vaccine. We systematically searched peer-reviewed studies during 2020-2022, examining analyses of the Chemical Composition of the COVID-19 Vaccine authorized in Indonesia. We also explored the related information from the official body. Finally, we constructed a short review of the public acceptance of the vaccine focusing on the chemical composition. All COVID-19 vaccines are intended to induce humoral and cellular immunity toward infection. The antigen causes this as an active ingredient of the vaccine. The vaccine also contains adjuvants, and some other chemicals are required. The expansion aims to maintain the content of the vaccine, strengthen the body's reaction to the vaccine, and facilitate the administration process. But there are concerns about the risk of unintended effects of the substances used. This perception includes those that hinder the implementation of COVID-19 Vaccination in Indonesia. There is a need to disseminate information and education about the vaccine composition so that the optimal vaccination program benefits the community.

You might also be interested in these eBooks
International Conference on Chemistry and Chemistry Education View Preview
Journal of Biomimetics, Biomaterials and Biomedical Engineering Vol. 63 View Preview

Info:

Periodical:

Journal of Biomimetics, Biomaterials and Biomedical Engineering (Volume 63)

Pages:

101-110

DOI:

https://doi.org/10.4028/p-b6Jawk

Citation:

Cite this paper

Online since:

November 2023

Authors:

Tonang Dwi Ardyanto*, Nurhasan Agung Prabowo, Risalina Myrtha, Laaily Shofiyah

Keywords:

Chemical Composition, COVID-19 Vaccine, Public Health

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2023 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

* - Corresponding Author

References

[1] WHO, Weekly epidemiological update on COVID-19 - 11 May 2021, (n.d.). https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021.

Google Scholar

[2] N.G. Davies, A.J. Kucharski, R.M. Eggo, A. Gimma, W.J. Edmunds, T. Jombart, K. O'Reilly, A. Endo, J. Hellewell, E.S. Nightingale, B.J. Quilty, C.I. Jarvis, T.W. Russell, P. Klepac, N.I. Bosse, S. Funk, S. Abbott, G.F. Medley, H. Gibbs, C.A.B. Pearson, S. Flasche, M. Jit, S. Clifford, K. Prem, C. Diamond, J. Emery, A.K. Deol, S.R. Procter, K. van Zandvoort, Y.F. Sun, J.D. Munday, A. Rosello, M. Auzenbergs, G. Knight, R.M.G.J. Houben, Y. Liu, Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study, The Lancet Public Health. 5 (2020) e375–e385.

DOI: 10.1016/S2468-2667(20)30133-X

Google Scholar

[3] N.A. Prabowo, H. Apriningsih, Colchicine reduces the degree of inflammation in COVID-19 patients, IOP Conf. Ser.: Earth Environ. Sci. 824 (2021) 012087.

DOI: 10.1088/1755-1315/824/1/012087

Google Scholar

[4] D.E. Speiser, M.F. Bachmann, COVID-19: Mechanisms of Vaccination and Immunity, Vaccines. 8 (2020) 404.

DOI: 10.3390/vaccines8030404

Google Scholar

[5] F. Krammer, SARS-CoV-2 vaccines in development, Nature. 586 (2020) 516–527.

DOI: 10.1038/s41586-020-2798-3

Google Scholar

[6] N. Sherina, A. Piralla, L. Du, H. Wan, M. Kumagai-Braesch, J. Andréll, S. Braesch-Andersen, I. Cassaniti, E. Percivalle, A. Sarasini, F. Bergami, R. Di Martino, M. Colaneri, M. Vecchia, M. Sambo, V. Zuccaro, R. Bruno, M. Sachs, T. Oggionni, F. Meloni, H. Abolhassani, F. Bertoglio, M. Schubert, M. Byrne-Steele, J. Han, M. Hust, Y. Xue, L. Hammarström, F. Baldanti, H. Marcotte, Q. Pan-Hammarström, Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection, Med. 2 (2021) 281-295.e4.

DOI: 10.1016/j.medj.2021.02.001

Google Scholar

[7] WHO, Update 52 – COVID-19 vaccines and immune response (8 March 2021)., (2022). https://www.who.int/publications/m/item/update-52-covid-19-vaccines-and-immune-response.

DOI: 10.26524/royal.37.9

Google Scholar

[8] WHO, The COVID-19 candidate vaccine landscape and tracker. 14 Mei 2021, (n.d.). .https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

Google Scholar

[9] J. Wang, Y. Peng, H. Xu, Z. Cui, R.O. Williams, The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation, AAPS PharmSciTech. 21 (2020) 225.

DOI: 10.1208/s12249-020-01744-7

Google Scholar

[10] Presidential of Indonesia, Presidential Decree of Indonesia number 99/2020 on the Procurement of Covid-19 Vaccine and Its Implementation, 2020 and being latest revision with Presidential Decree number 14/2021, 2021.

DOI: 10.21070/acopen.3.2020.733

Google Scholar

[11] Indonesian Ministry of Health., Guideline book of Imunization, Jakarta, 2017.

Google Scholar

[12] WHO, Vaccine Safety in immunization Programmes. Vaccine Safety Basics., (2022). https://vaccine-safety-training.org/vaccine-safety-in-immunization-programmes.html Accessed on 14 August 2022.

DOI: 10.1016/s0264-410x(00)00358-3

Google Scholar

[13] CA Siegrist, Vaccine Immunology (General Aspects of Vaccination)., 2008. http://www.who.int/immunization/documents/Elsevier_Vaccine_immunology.pdf.

Google Scholar

[14] R. Levi, E. Azzolini, C. Pozzi, L. Ubaldi, M. Lagioia, A. Mantovani, M. Rescigno, One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19, J Clin Invest. 131 (2021) 149154.

DOI: 10.1172/JCI149154

Google Scholar

[15] A. Mazzoni, N. Di Lauria, L. Maggi, L. Salvati, A. Vanni, M. Capone, G. Lamacchia, E. Mantengoli, M. Spinicci, L. Zammarchi, S.T. Kiros, A. Rocca, F. Lagi, M.G. Colao, P. Parronchi, C. Scaletti, L. Turco, F. Liotta, G.M. Rossolini, L. Cosmi, A. Bartoloni, F. Annunziato, First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19, Journal of Clinical Investigation. 131 (2021) e149150.

DOI: 10.1172/JCI149150

Google Scholar

[16] N.G. Kounis, I. Koniari, C. de Gregorio, D. Velissaris, K. Petalas, A. Brinia, S.F. Assimakopoulos, C. Gogos, S.N. Kouni, G.N. Kounis, G. Calogiuri, M.-Y. Hung, Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations, Vaccines. 9 (2021) 221.

DOI: 10.3390/vaccines9030221

Google Scholar

[17] WHO, Vaccination against COVID-19 with the Sinovac-CoronaVac COVID-19 vaccine, (2021). https://www.who.int/docs/librariesprovider2/default-document-library/sinovac-quick-guide-covid-19-eng.pdf.

DOI: 10.5935/0004-2749.20220070

Google Scholar

[18] National Food and Drug Supervisory Agency, The Factsheet of Coronavac, (2022). https://pionas.pom.go.id/obat-baru/coronavac-suspensi-injeksi-3-mcg05-ml.

Google Scholar

[19] Indonesian Ministry of Health, National Covid-19 Vaccination Dashboard, (n.d.). https://vaksin.kemkes.go.id/#/vaccines (accessed August 14, 2022).

Google Scholar

[20] A. Kandeil, A. Mostafa, R.R. Hegazy, R. El-Shesheny, A. El Taweel, M.R. Gomaa, M. Shehata, M.A. Elbaset, A.E. Kayed, S.H. Mahmoud, Y. Moatasim, O. Kutkat, N.N. Yassen, M.E. Shabana, M. GabAllah, M.N. Kamel, N.M. Abo Shama, M. El Sayes, A.N. Ahmed, Z.S. Elalfy, B.M. Mohamed, S.N. Abd El-Fattah, H.M. El Hariri, M. Abdel Kader, O. Azmy, G. Kayali, M.A. Ali, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies, Vaccines. 9 (2021) 214.

DOI: 10.3390/vaccines9030214

Google Scholar

[21] W. and U. Indonesian Ministry of Health, Covid-19 Vaccine Acceptance Survey in Indonesia, (2020). (https://covid19.go.id/storage/app/media/Hasil%20Kajian/2020/November/vaccine-acceptance-survey-id-12-11-2020final.pdf.

Google Scholar

[22] Indonesian Ulema Counci, The Fatwa on the Usage of Sinovac Covid-19 Vaccine, (2020). (https://mui.or.id/wp-content/uploads/2021/01/Fatwa-MUI-Nomor-2-Tahun-2021-tentang-produk-vaksin-covid-19-dari-Sinovac-Bio-Farma.pdf 11 January 2020.

DOI: 10.52431/tafaqquh.v8i1.298

Google Scholar

[23] BioFarma, Bio Farma Ready to Supply Covid-19 Vaccine Up to 18 Million Doses, (2021). https://www.biofarma.co.id/en/latest-news/detail/bio-farma-ready-to-supply-covid19-vaccine-up-to-18-million-doses accessed on 15 August 2022.

Google Scholar

[24] J. Wibowo, R.S. Heriyanto, F. Wijovi, D.A. Halim, C. Claudia, E. Marcella, B. Susanto, M. Indrawan, N.K. Heryadi, M. Imanuelly, J.J. Anurantha, T.I. Hariyanto, C. Marcellin, T.D. Sinaga, S.A. Rizki, N. Sieto, J.I. Siregar, N.P.H. Lugito, A. Kurniawan, Factors associated with side effects of COVID-19 vaccine in Indonesia, Clin Exp Vaccine Res. 11 (2022) 89–95.

DOI: 10.7774/cevr.2022.11.1.89

Google Scholar

[25] E. Mahase, Astra Zeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude, BMJ. (2021) n931.

DOI: 10.1136/bmj.n931

Google Scholar

[26] N. Novak, L. Tordesillas, B. Cabanillas, Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia, Int Rev Immunol. 41 (2022) 438–447.

DOI: 10.1080/08830185.2021.1939696

Google Scholar

[27] E. Dolgin, The tangled history of mRNA vaccines, Nature. 597 (2021) 318–324.

DOI: 10.1038/d41586-021-02483-w

Google Scholar

[28] M.E. Oster, D.K. Shay, J.R. Su, J. Gee, C.B. Creech, K.R. Broder, K. Edwards, J.H. Soslow, J.M. Dendy, E. Schlaudecker, S.M. Lang, E.D. Barnett, F.L. Ruberg, M.J. Smith, M.J. Campbell, R.D. Lopes, L.S. Sperling, J.A. Baumblatt, D.L. Thompson, P.L. Marquez, P. Strid, J. Woo, R. Pugsley, S. Reagan-Steiner, F. DeStefano, T.T. Shimabukuro, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021, JAMA. 327 (2022) 331.

DOI: 10.1001/jama.2021.24110

Google Scholar

[29] The Ministry of Health Indonesia, NITAG, UNICEF, and WHO, COVID-19 Vaccine Acceptance Survey in Indonesia, (2020). https://covid19.go.id/storage/app/media/Hasil%20Kajian/2020/November/ vaccine-acceptance-survey-en-12-11-2020final.pdf.

Google Scholar

[30] Ourworldindata.org, Total number of people who have completed the initial vaccination protocol, (2022). https://ourworldindata.org/covid-vaccinations , accesses on 30 March 2022.

Google Scholar

© 2025 Trans Tech Publications Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For open access content, terms of the Creative Commons licensing CC-BY are applied.
Scientific.Net is a registered trademark of Trans Tech Publications Ltd.